ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44+/CD24-/low stem cells in different molecular subtypes of breast cancer

在乳腺癌的不同分子亚型中,ALDH1+ 干细胞比 CD44+/CD24-/low 干细胞表现出更多的干细胞样特征

阅读:10
作者:Jie Chen #, Shiwei Liu #, Yingying Su, Xiao Zhang

Background

CD44+/CD24 - /low and ALDH1+ are both markers of breast cancer stem cell (BCSC), we compared the biological characteristics of CD44+/CD24 - /low and ALDH1+ BCSCs in the four molecular subtypes of breast cancer.

Conclusions

In the four molecular subtypes of breast cancer, ALDH1+ BCSC demonstrated better self-renewal and tumorigenic abilities than CD44+/CD24 - /low BCSC.

Methods

Four fresh blocks of breast cancer tissue were obtained from patients with Luminal A, Luminal B, human epidermal receptor-2 (HER2)-overexpression and triple-negative breast cancer, respectively. Flow cytometry was used to sort CD44+/CD24 - /low and ALDH1+ BCSCs. The mammosphere (MS) formation experiment and NOD/SCID mouse xenograft experiment were performed to compare the self-renewal and tumorigenic abilities of CD44+/CD24 - /low with those of ALDH1+ BCSCs.

Results

The proportions of CD44+/CD24 - /low BCSC and ALDH1+ BCSC in Luminal A, Luminal B, HER2 overexpression and triple-negative subtypes were 12.1% and 8.7%, 2.7% and 5.7%, 0.8% and 8.7%, 0.7% and 4.5%, respectively. The MS formation experiment demonstrated that ALDH1+ BCSC formed significantly more MSs than CD44+/CD24 - /low BCSC in the four molecular subtypes (P<0.001). The NOD/SCID mouse xenograft experiment demonstrated that the sizes of grafted tumors formed by ALDH1+ BCSC were larger than those formed by CD44+/CD24 - /low BCSC in the four molecular subtypes (P<0.05). Conclusions: In the four molecular subtypes of breast cancer, ALDH1+ BCSC demonstrated better self-renewal and tumorigenic abilities than CD44+/CD24 - /low BCSC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。